Paper1648142
Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
Fukuoka M and 7 others. J Natl Cancer Inst, 1991. Cited by 377 papers, by iCite.
Cite this record
ConductScience Library. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. Papers, record 1648142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1648142
- Disease
- small cell lung carcinoma367 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.
- PubMed
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Small Cell | Major topic |
| Lung Neoplasms | Major topic |
| Adult | |
| Aged | |
| Cisplatin | |
| Cyclophosphamide | |
| Doxorubicin | |
| Drug Administration Schedule | |
| Etoposide | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Vincristine |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01752517 | Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer | Results |
Source ClinicalTrials.gov
Cited by87
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 377 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41331590 | Prognostic role of prognostic nutritional index change in patients with extensive stage small cell lung cancer treated with platinum-based chemotherapy. | BMC Cancer | 2025 | https://conductscience.org/library/papers/41331590 | PubMed |
| 37871898 | The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study. | Cancer Res Treat | 2024 | https://conductscience.org/library/papers/37871898 | PubMed |
| 37175833 | Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37175833 | PubMed |
| 36977572 | Primary tracheal small-cell carcinoma detected 11 months after surgery for pulmonary large-cell neuroendocrine carcinoma: A case report. | Thorac Cancer | 2023 | https://conductscience.org/library/papers/36977572 | PubMed |
| 36900334 | Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36900334 | PubMed |
| 35925272 | [Small cell lung cancer-Established standards and new approaches]. | Inn Med (Heidelb) | 2022 | https://conductscience.org/library/papers/35925272 | PubMed |
| 35254612 | Neuroendocrine Tumors: a Relevant Clinical Update. | Curr Oncol Rep | 2022 | https://conductscience.org/library/papers/35254612 | PubMed |
| 34946283 | Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract. | Medicina (Kaunas) | 2021 | https://conductscience.org/library/papers/34946283 | PubMed |
| 34902832 | Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 | https://conductscience.org/library/papers/34902832 | PubMed |
| 34757446 | Update 2021: Management of Small Cell Lung Cancer. | Lung | 2021 | https://conductscience.org/library/papers/34757446 | PubMed |
| 34532422 | Effectiveness and safety of bevacizumab in extensive-disease small cell lung cancer: a systemic review and meta-analysis. | Ann Transl Med | 2021 | https://conductscience.org/library/papers/34532422 | PubMed |
| 34430355 | Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1. | Transl Lung Cancer Res | 2021 | https://conductscience.org/library/papers/34430355 | PubMed |
| 34164166 | Role of surgery in a case-control study of patients with clinical stage IIIA small cell lung cancer. | J Thorac Dis | 2021 | https://conductscience.org/library/papers/34164166 | PubMed |
| 33568748 | Clinical considerations for the management of androgen indifferent prostate cancer. | Prostate Cancer Prostatic Dis | 2021 | https://conductscience.org/library/papers/33568748 | PubMed |
| 33525370 | Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I-IV Stage. | Medicina (Kaunas) | 2021 | https://conductscience.org/library/papers/33525370 | PubMed |
| 33521370 | Current and future strategies in radiotherapy for small-cell lung cancer. | J Clin Transl Res | 2020 | https://conductscience.org/library/papers/33521370 | PubMed |
| 32751469 | Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. | J Clin Med | 2020 | https://conductscience.org/library/papers/32751469 | PubMed |
| 32706170 | Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer. | Thorac Cancer | 2020 | https://conductscience.org/library/papers/32706170 | PubMed |
| 32544169 | Comparative genomics of high grade neuroendocrine carcinoma of the cervix. | PLoS One | 2020 | https://conductscience.org/library/papers/32544169 | PubMed |
| 29535913 | Current standards for clinical management of small cell lung cancer. | Transl Lung Cancer Res | 2018 | https://conductscience.org/library/papers/29535913 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| IFOSFAMIDE | CHEMBL1024 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1024 | ChEMBL |
| VINORELBINE | CHEMBL553025 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL553025 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1648142
GET https://conductscience.org/api/papers/v1/1648142/cited_by?page=2